This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Observational Study on the Long Term Safety of Kuvan® Treatment in Patients With Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or BH4 Deficiency (KAMPER)

This study is currently recruiting participants.
See Contacts and Locations
Verified May 2016 by BioMarin Pharmaceutical
Sponsor:
Information provided by (Responsible Party):
BioMarin Pharmaceutical
ClinicalTrials.gov Identifier:
NCT01016392
First received: November 18, 2009
Last updated: May 24, 2016
Last verified: May 2016
  Purpose

Kuvan® is a synthetic copy of a body's own substance called tetrahydrobiopterin (BH4). BH4 is required by the body to use an amino acid called phenylalanine in order to build another substance called tyrosine.

Kuvan® received marketed authorisation in Europe in December 2008 and is now available in several European countries for the treatment of Hyperphenylalaninemia (HPA).

The primary objective is to assess the long-term safety in subjects treated with Kuvan®.

Secondary objectives are to provide additional information regarding:

  • Safety in specific subject groups (elderly, pediatric, pregnant women and subjects with renal or hepatic insufficiency).
  • Growth and neurocognitive outcomes for subjects with hyperphenylalaninemia (HPA) who are receiving treatment with Kuvan®.
  • Progress and outcome of pregnancy for women with HPA who become pregnant while receiving treatment with Kuvan® (these women will be enrolled in a dedicated sub-registry).
  • Assessment of adherence to diet and to Kuvan®.
  • Assessment of long-term sensitivity to Kuvan®treatment.

Condition
Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or Tetrahydrobiopterin (BH4) Deficiency

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Kuvan® Adult Maternal Pediatric European Registry

Resource links provided by NLM:


Further study details as provided by BioMarin Pharmaceutical:

Primary Outcome Measures:
  • Incidence and description of Adverse Events and Serious Adverse Events (AEs/SAEs) [ Time Frame: A maximum of 15 years treatment duration. ]

Secondary Outcome Measures:
  • Incidence of AEs/SAEs in specific population (elderly, children, subjects with renal or hepatic insufficiency) [ Time Frame: A maximum of 15 years treatment duration. ]
  • Description on somatic growth (in BH4 deficient children < 3 years) [ Time Frame: A maximum of 15 years treatment duration. ]
  • Neurocognitive outcomes [ Time Frame: A maximum of 15 years treatment duration. ]
  • Neurological and psychiatric assessment [ Time Frame: A maximum of 15 years treatment duration. ]
  • Diet and Kuvan® treatment adherence [ Time Frame: A maximum of 15 years treatment duration. ]
  • Long-term sensitivity to Kuvan® treatment [ Time Frame: A maximum of 15 years treatment duration. ]
  • Blood Phe levels [ Time Frame: A maximum of 15 years treatment duration. ]
  • Tyrosine (Tyr) levels [ Time Frame: A maximum of 15 years treatment duration. ]
  • Pregnancy and delivery outcomes [ Time Frame: A maximum of 15 years treatment duration. ]

Estimated Enrollment: 625
Study Start Date: December 2009
Estimated Study Completion Date: December 2024
Estimated Primary Completion Date: December 2024 (Final data collection date for primary outcome measure)
Detailed Description:
This is an observational, multicenter, drug registry Study. The study will have a total duration of 15 years, including a 10-year inclusion period. No diagnostic, therapeutic or experimental intervention is involved. Subjects will receive clinical assessments, medications and treatments solely as determined by their study physician.
  Eligibility

Ages Eligible for Study:   4 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

All subjects with HPA due to PKU or BH4 deficiency followed at participating centres.

And specific groups (elderly, pediatric, pregnant women and subjects with renal or hepatic insufficiency).

Criteria

Inclusion Criteria:

• Adult or pediatric subject (4 years old or older) of either gender with HPA due to PKU.

Or

  • Adult or pediatric subject (no lower limit of age) of either gender with HPA due to BH4 deficiency
  • Have been shown to be responsive to BH4 or Kuvan. (Note: For Spain only-Have been shown to be responsive to BH4 or for the newly diagnosed subjects to be responsive to Kuvan as defined in the Summary of Product Characteristics [SmPC])
  • Currently being treated with Kuvan® at a participating centre
  • Subject or parent/legal guardian willing and able to provide written signed informed consent and given before any data collection. If a child is old enough to read and write, a separate assent form will be given
  • Have been shown to be responsive to BH4 or for the newly diagnosed subjects fo be responsive to Kuvan as defined in the SmPC

Exclusion Criteria:

  • Known hypersensitivity to Kuvan®
  • Legal incapacity or limited legal capacity without legal guardian representation
  • Breast-feeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01016392

Contacts
Contact: Ignacio Alvarez, Dr ignacio.alvarez@bmrn.com

  Show 80 Study Locations
Sponsors and Collaborators
BioMarin Pharmaceutical
Investigators
Study Director: Medical Director BioMarin Pharmaceutical
  More Information

Responsible Party: BioMarin Pharmaceutical
ClinicalTrials.gov Identifier: NCT01016392     History of Changes
Other Study ID Numbers: EMR700773-001
Study First Received: November 18, 2009
Last Updated: May 24, 2016

Keywords provided by BioMarin Pharmaceutical:
Observational post-authorization safety study on Kuvan®.

Additional relevant MeSH terms:
Phenylketonurias
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Amino Acid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases

ClinicalTrials.gov processed this record on August 21, 2017